Table 5.
(a) The discounted incremental costs, benefits and cost-effectiveness ratios (ICERs) for treatment alternatives in comparison with no treatment of HBeAg-positive chronic hepatitis B (CHB); (b) The discounted ICERs for treatment alternatives in comparison with no treatment of HBeAg-negative CHB
| Treatment alternatives | Cost (S$) | Life year gained | QALY | Cost per Life Year gained (S$/LY) | Cost per QALY gained (S$/QALY) |
|---|---|---|---|---|---|
| (a) | |||||
| IFN | 6818.65 | 0.273 | 0.110 | 24 952.35 | 61 940.92 |
| PEG-IFN (1 year) | 19 216.05 | 0.566 | 0.570 | 33 977.06 | 33 718.47 |
| Lamivudine (1 year) | 2247.74 | 0.324 | 0.319 | 6943.59 | 7053.58 |
| Adefovir (1 year) | 2982.83 | 0.275 | 0.298 | 10 830.09 | 9993.50 |
| Lamivudine (5 years) | 8031.34 | 0.644 | 0.631 | 12 476.32 | 12 724.48 |
| Adefovir (5 years) | 11 237.25 | 0.738 | 0.740 | 15 223.13 | 15 176.56 |
| Lamivudine + adefovir as rescue (5 years) | 8455.30 | 0.872 | 0.854 | 9695.47 | 9905.72 |
| Adefovir + lamivudine as rescue (5 years) | 10 845.16 | 0.805 | 0.813 | 13 472.82 | 13 344.85 |
| (b) | |||||
| PEG-IFN (1 year) | 19 785.52 | 0.642 | 0.486 | 30 833.44 | 40 707.14 |
| Lamivudine (1 year) | 1928.59 | 0.625 | 0.568 | 3086.05 | 3393.32 |
| Adefovir (1 year) | 2863.18 | 0.516 | 0.471 | 5546.03 | 6078.79 |
| Lamivudine (5 years) | 10 807.30 | 1.133 | 1.077 | 9535.13 | 10 034.00 |
| Adefovir (5 years) | 13 471.57 | 1.731 | 1.665 | 7784.26 | 8090.25 |
| Lamivudine + adefovir as rescue (5 years) | 10 750.93 | 1.838 | 1.740 | 5848.71 | 6178.02 |
| Adefovir + lamivudine as rescue (5 years) | 13 111.95 | 1.887 | 1.816 | 6948.67 | 7218.64 |